Fig. 3.

Longitudinal analysis of plasma cell-free DNA mutations shows the correlation with treatment outcomes. (A, B) Patients with a decrease in mutation volume at the end of treatment (log change in genome equivalents ≥ 1.5) showed better progression-free and overall survival than patients showing increased mutation volume (log change in genome equivalents < 0) or a small decrease in mutation volume (log change in genome equivalents < 1.5). (C) A 61-year-old male with PTCL-NOS maintained a CR with loss of a TP53 mutation. (D) A 65-year-old female with PTCL-NOS showing an increase in a TP53 mutation at the end of treatment finally relapsed. (E) A 59-year-old male with PTCL-NOS maintained a complete response with a decrease in initially detected mutations including EZH2. (F) A 58-year-old male with AITL showed increases in CREBBP and MEF2B mutations after autologous stem cell transplantation and relapsed during follow-up. (G) A 50-year-old male with relapsed AITL showed increases in TP53 and SOCS1 mutations after salvage treatment during disease progression. (H) A 34-year-old female with ALK-positive ALCL showed increases in CREBBP and STAT6 mutation volumes after salvage therapy. AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; ASCT, autologous stem cell transplantation; CR, complete response; GE, genome equivalent; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified.